Instrument Inactif

Communiqués CEL-SCI Corporation Nyse

Actions

US1508374097

Cours en clôture Nyse Autres places de cotation
- ^USD	-

15/05	CEL-SCI Corporation annonce ses résultats pour le deuxième trimestre et le semestre clos le 31 mars 2024	CI
08/05	Cel-Sci obtient l'autorisation de la FDA américaine de procéder à une étude de confirmation pour son médicament contre le cancer Multikine	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population	18/06	BU
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor	06/06	BU
Cel-Sci: Fiscal Q2 Earnings Snapshot	16/05	AQ
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results	16/05	BU
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head and Neck Cancer	09/05	AQ
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	08/05	BU
CEL-SCI Appoints Mario Gobbo to Its Board of Directors	23/04	BU
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology	19/03	BU
CEL-SCI Corporation Issues Letter to Shareholders	06/03	BU
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results	15/02	BU
Cel-Sci: Fiscal Q1 Earnings Snapshot	14/02	AQ
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock	13/02	BU
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock	12/02	AQ
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock	09/02	BU
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head and Neck Cancer Drug	07/02	AQ
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug	06/02	BU
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path towards Marketing Authorization for Multikine	01/02	AQ
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®	31/01	BU
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments	22/12	BU
UK'S National Institute for Health and Care Excellence Selects CEL-SCI's Multikine as Potential New Standard of Care for Head and Neck Cancer	05/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués CEL-SCI Corporation Nyse

Actions

US1508374097

Communiqués

Filtres